existing and new tools, technologies and systems. Key action: HHS will complete a full assessment of requirements for vaccine and therapeutics and determine the most effective approach to impacting the spread of an influenza pandemic. Key action: HHS will support development of multiple, safe and broad-spectrum therapeutics for use in seriously ill and/or hospitalized patients, including pediatric patients. HHS intends to continue supporting informative clinical trials until at least two new influenza therapeutics are found to have sufficient evidence of safety and effectiveness to support approval. Key action: HHS will support the development and effectiveness evaluation of reusable respiratory protective devices for the reduction of transmission of influenza viruses to and/or from patient and health care provider. Key actio n: HHS will update the prioritization of vaccine recipients to have the greatest impact on health, community resilience and risk mitigation during an influenza pandemic. Advances in developing and strategically sourcing vaccines and other MCMs in the past decade have provided a variety of effective and rapidly available options for a pandemic. Still, the time required between identification of a pandemic influenza virus and full production capacity and distribution of vaccines limits their availability. To achieve the goal of vaccine delivery within weeks, rapidly developing, licensing, and producing a sensitive and specific test for the pandemic influenza virus is critical. Supporting end-user engagement for all new MCM development to ensure alignment ent practices or to up with curr date and/or shape practices to align with new medical products is critical to ensure products developed may be optimally used. In the long term, aggressive translation of applied research in diagnostics, therapeutics, and vaccines may yield breakthrough MCMs to mitigate the next influenza pandemic. 26